Latest News and Press Releases

ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempted...

The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic.  MUNICH, GERMANY, May 20, 2025 – Tubulis today...

VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today the...

ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp....

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE")...

Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeuticsFocus on breakthrough ADC payloads and immuno-oncology candidates with out-licensing potential ...

Adcytherix se lance et lève 30 millions d'euros en amorçage pour développer des anticorps-conjugués de nouvelle génération L'objectif est de créer un leader dans le développement d'ADC pour traiter...

Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. ...

LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies...

Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.